ArticleProstate cancer and prostatic diseases2013
Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer.
Article in Prostate cancer and prostatic diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- Trial
- Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists' practices.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Oncologists' responsibility, comfort, and knowledge managing hyperglycemia in patients with cancer undergoing chemotherapy: a cross sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation.The Journal of clinical investigation · 2023Article
- Article
- Novel plasma exosome biomarkers for prostate cancer progression in co-morbid metabolic disease.Advances in cancer biology - metastasis · 2022Article
- Diabetes and the Prostate: Elevated Fasting Glucose, Insulin Resistance and Higher Levels of Adrenal Steroids in Prostate Cancer.Journal of clinical medicine · 2022Article
- Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2022Article
- Review
- Oxygen and metabolic reprogramming in the tumor microenvironment influences metastasis homing.Cancer biology & therapy · 2021Review
- High glucose: an emerging association between diabetes mellitus and cancer progression.Journal of molecular medicine (Berlin, Germany) · 2021Review
- The Influence of Anti-Diabetic Drugs on Prostate Cancer.Cancers · 2021Review
- The Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer and the Benefits and Potential Anti-oncogenic Mechanisms of Progressive Resistance Training.Sports medicine - open · 2020Article
- Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS).Contemporary clinical trials · 2019Article
- Pre-diagnostic carbohydrate intake and treatment failure after radical prostatectomy for early-stage prostate cancer.Cancer causes & control : CCC · 2019Article
- Hyperglycemia and aberrant O-GlcNAcylation: contributions to tumor progression.Journal of bioenergetics and biomembranes · 2018Review
- Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities.Oncology nursing forum · 2017Review
- The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC.The Prostate · 2017Article
- Prostate-specific antigen nadir concentration, hypertension and diabetes as risk factors for biochemical failure after permanentMolecular and clinical oncology · 2016Article
- Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies.Translational oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundObesity is consistently linked with prostate cancer (PCa) recurrence and mortality, though the mechanism is unknown. Impaired glucose regulation, which is common among obese individuals, has been hypothesized as a potential mechanism for PCa tumor growth. In this study, we explore the relationship between serum glucose at time of treatment and risk of PCa recurrence following initial therapy.
methodsThe study group comprised 1734 men treated with radical prostatectomy (RP) or radiation therapy (RT) for localized PCa between 2001-2010. Serum glucose levels closest to date of diagnosis were determined. PCa recurrence was determined based on PSA progression (nadir PSA+2 for RT; PSA≥0.2 for RP) or secondary therapy. Multivariate Cox regression was performed to determine whether glucose level was associated with biochemical recurrence after adjusting for age, race, body mass index, comorbidity, diagnosis of diabetes, Gleason Sum, PSA, treatment and treatment year.
resultsRecurrence was identified in 16% of men over a mean follow-up period of 41 months (range 1-121 months). Those with elevated glucose (≥100 mg/dl) had a 50% increased risk of recurrence (HR 1.5, 95% CI: 1.1-2.0) compared with those with a normal glucose level (<100 mg/dl). This effect was seen in both those undergoing RP (HR 1.9, 95% CI: 1.0-3.6) and those treated with RT (HR 1.4, 95% CI: 1.0-2.0).
conclusionsGlucose levels at the time of PCa diagnosis are an independent predictor of PCa recurrence for men undergoing treatment for localized disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.